Ireland
--:--IST
Recruiting Phase 2

BPC 157 for Acute Hamstring Muscle Strain Repair

NCT07437547 · tracked via the Priya Life Science China tracker
Phase
Phase 2
Started
2026-02-02
Last updated
2026-02-27

Condition(s) studied

Hamstring Muscle StrainSkeletal Muscle Injury

Investigational drug(s) / intervention(s)

Pentadecapeptide BPC 157Placebo

Pentadecapeptide BPC 157: subcutaneous injection (administered by trained study staff). Schedule: once daily for 14 days.

Placebo: subcutaneous injection (administered by trained study staff). Schedule: once daily for 14 days.

Study summary

This randomized, double-blind, placebo-controlled Phase 2 study evaluates whether pentadecapeptide BPC 157 (BPC-157), an investigational peptide, can speed structural healing and functional recovery after an acute grade II hamstring muscle strain. Participants will receive BPC 157 or placebo for 14 days in addition to a standardized rehabilitation program. The co-primary endpoints are time to return to unrestricted sport and change in MRI-assessed injury volume at Day 14.

Eligibility

Sex
ALL
Min age
18 Years
Max age
45 Years
Healthy volunteers
No
Inclusion Criteria: * Age 18 to 45 years. * Acute posterior thigh pain consistent with hamstring strain with onset within 72 hours prior to screening. * MRI-confirmed grade II hamstring strain of the biceps femoris, semitendinosus, or semimembranosus, with measurable lesion. * Pre-injury physical activity \>= 3 sessions/week or participation in organized recreational sport. * Willingness to follow the standardized rehabilitation protocol and attend all study visits. * For participants of childbearing potential: negative pregnancy test at baseline and agreement to use effective contraception during dosing and for 30 days after last dose. Exclusion Criteria: * Grade III hamstring tear, tendon avulsion, or injury requiring surgical management. * Concomitant lower extremity injury that would interfere with rehabilitation or outcome assessment. * Prior hamstring strain on the index limb within the past 6 months. * Use of systemic corticosteroids, anabolic agents, platelet-rich plasma, stem-cell products, or investigational peptides/growth factors within 30 days prior to screening. * Known bleeding disorder or current therapeutic anticoagulation. * Significant uncontrolled medical illness (e.g., severe cardiovascular, hepatic, or renal disease) that increases study risk. * Known allergy or hypersensitivity to components of the investigational product or placebo. * Pregnant or breastfeeding. * Current participation in another interventional clinical study or participation within 30 days prior to screening. * Currently subject to a formal anti-doping testing program (e.g., WADA/USADA-aligned) where use of an investigational peptide could create a regulatory conflict, unless explicitly approved by the relevant authority

Primary outcome measure(s)

  • Time to return to unrestricted sport participation (days) — 8 Weeks
    defined as clearance by a blinded sports medicine clinician and completion of a standardized functional performance battery without pain-limited stopping.
  • Change from baseline to Day 14 in MRI-assessed hamstring injury volume (cm^3), measured by blinded central radiology review. — 14 Days

Trial sites (1)

FacilityCityRegionStatus
Peking University Shenzhen Hospital Shenzhen Guangdong Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07437547 on ClinicalTrials.gov ↗ ← All trials in China